Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;49(6):429-438.
doi: 10.1053/j.seminoncol.2023.01.004. Epub 2023 Jan 27.

A narrative review of the principal glucocorticoids employed in cancer

Affiliations
Review

A narrative review of the principal glucocorticoids employed in cancer

Nerina Denaro et al. Semin Oncol. 2022 Dec.

Abstract

Glucocorticoids (GCs) are a pharmacological class of drugs widely used in oncology in both supportive and palliative settings. GCs differentially impact organs with immediate and long-term effects; with suppressive effect on the immune system anchoring their use to manage the toxicities of immune checkpoint inhibitors (ICIs). In addition, GCs are often used in the management of symptoms related to cancer or chemotherapy and as adjuvants in the treatment of pain in the management of other. In the palliative setting, GCs, especially administered subcutaneously can be to assist in the control of nausea, dyspnea, asthenia, and anorexia-cachexia syndrome. In this narrative review, we aim to summarize the role of GCs in the different settings (curative, supportive, and palliative) to help clinicians use these important drugs in their daily clinical practice with cancer patients.

Keywords: Glucocorticoids; Immune checkpoint inhibitors; Oncology; Palliative care; Supportive care.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest B.P. was supported by ESMO with a Clinical Translational Fellowship aid supported by Roche. M.S. acted as consultant for MSD, BMS, Astra-Zeneca, Mercks, Amgen and Servier and received speaker honoraria from MSD, Mercks, Amgen ans Servier. A.M. received research grants from Roche and honoraria from Lilly, Novartis, EISAI, Seagen, Daiichi-Sankyo.

Substances

LinkOut - more resources